A work group formed by the Alzheimer’s Association has updated the criteria for diagnosing and staging Alzheimer’s disease. The new criteria incorporate fluid and imaging biomarkers and aim to define the disease biologically rather than based on symptoms. Core biomarkers have been identified to measure neuropathologic changes and disease severity. The revised criteria provide flexibility in using different diagnostic tools, such as plasma or PET scans. The work group emphasizes the role of clinicians in the diagnostic process. Funding for this research was provided by various organizations. The revised criteria are seen as a starting point for the development of formal clinical guidelines.
Source link
Revised Criteria for AD Diagnosis, Staging Released
